Dr. Hoenle AG (HNL) AI Stock Analysis

• Market Cap: €45.10M
• Dividend Yield: N/A
• Average Volume (3M): 6.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: -2.20%
• EPS Growth: -153.32%
• Country: DE
• Employees: 585
• Sector: Industrials
• Sector Strength: 72
• Industry: Electrical Equipment & Parts
• EPS (TTM): -0.15
• Shares Outstanding: 6,062,930
• 10 Day Avg. Volume: 3,193
• 30 Day Avg. Volume: 6,130
• PEG Ratio: -0.26
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 0.72
• P/FCF Ratio: 20.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: €7.00 ▼(-3.58% Downside)

Dr. Hoenle AG's overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges with declining revenues and persistent losses. Technical indicators show bearish momentum, with the stock trading below key moving averages. Valuation concerns are heightened by a negative P/E ratio and lack of dividend yield, making the stock less attractive to investors.

Dr. Hoenle AG Business Overview & Revenue Model

Company Description

Dr. Hoenle AG (HNL) is a leading provider of industrial UV technology, specializing in the development and production of high-quality UV systems for various applications, including printing, coatings, adhesives, and disinfection. The company operates primarily in the sectors of UV curing technology, UV systems for water treatment, and UV disinfection solutions, catering to a diverse range of industries such as automotive, healthcare, and manufacturing. HNL is known for its innovative products that enhance efficiency and sustainability in industrial processes.

How the Company Makes Money

Dr. Hoenle AG generates revenue primarily through the sale of its UV technology products and systems, which include UV lamps, UV curing systems, and disinfection solutions. The company has established key revenue streams from both domestic and international markets, leveraging its expertise to serve various industries. Additionally, HNL may earn income from service contracts, maintenance agreements, and partnerships with manufacturers and distributors that enhance market reach. Strategic alliances with companies in related sectors also contribute to its earnings by facilitating technology integration and expanding product applications.

Dr. Hoenle AG Financial Statement Overview

Summary

Dr. Hoenle AG faces significant financial challenges, with declining revenues and persistent losses impacting profitability. While the balance sheet shows moderate leverage, the negative return on equity and operational inefficiencies are concerning. Cash flow improvements are a positive sign, but the company must focus on enhancing operational performance and profitability to ensure long-term financial stability.

Income Statement

Dr. Hoenle AG's income statement reveals significant challenges. The company has experienced declining revenue over recent periods, with a TTM revenue growth rate of -1.34%. Profitability metrics are concerning, with negative net profit and EBIT margins, indicating operational inefficiencies and potential cost management issues. The gross profit margin remains relatively stable, suggesting some resilience in core operations.

Balance Sheet

The balance sheet shows moderate financial stability. The debt-to-equity ratio is at 0.65, indicating a manageable level of leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio stands at 52.3%, suggesting a reasonable level of equity financing relative to assets, but the company needs to address profitability to improve overall financial health.

Cash Flow

Cash flow analysis shows mixed results. The operating cash flow to net income ratio is positive, indicating some cash generation capability despite net losses. Free cash flow has grown significantly by 60.39% in the TTM period, which is a positive sign. However, the free cash flow to net income ratio suggests reliance on non-operational cash inflows, highlighting the need for improved operational performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	96.48M	98.73M	106.34M	116.09M	115.17M	93.88M
Gross Profit	57.53M	60.07M	53.35M	69.28M	69.34M	60.54M
EBITDA	2.62M	3.02M	539.00K	20.41M	14.02M	14.82M
Net Income	-13.59M	-13.28M	-11.01M	-13.36M	-4.82M	5.68M
Balance Sheet
Total Assets	149.36M	155.38M	176.16M	195.46M	202.91M	196.20M
Cash, Cash Equivalents and Short-Term Investments	5.91M	7.51M	9.32M	7.13M	12.07M	34.17M
Total Debt	50.80M	53.24M	56.89M	59.53M	53.64M	46.41M
Total Liabilities	71.11M	75.70M	80.02M	88.22M	91.78M	79.51M
Stockholders Equity	78.12M	79.42M	95.82M	106.88M	110.72M	116.34M
Cash Flow
Free Cash Flow	2.96M	3.44M	209.00K	-11.71M	-15.96M	-22.96M
Operating Cash Flow	4.90M	5.53M	3.14M	-7.41M	1.13M	7.23M
Investing Cash Flow	-195.00K	-2.37M	2.65M	-1.69M	-24.50M	-30.74M
Financing Cash Flow	-5.62M	-4.90M	-3.42M	3.73M	1.25M	43.25M

Dr. Hoenle AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HNL, the sentiment is Negative. The current price of 7.26 is below the 20-day moving average (MA) of 7.72, below the 50-day MA of 8.14, and below the 200-day MA of 9.05, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 31.07 is Neutral, neither overbought nor oversold. The STOCH value of 14.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:HNL.

Dr. Hoenle AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
S188	60 Neutral	€34.75M	9.05	4.50%	3.31%	76.29%	347.70%
MSAG	43 Neutral	€41.27M	-5.66	-11.55%	―	-40.37%	-406.54%
HNL	42 Neutral	€45.10M	-3.32	-15.84%	―	-2.20%	-153.32%

Dr. Hoenle AG Corporate Events

Hoenle AG Pre-announces Financial Reports for 2024/25

Hoenle AG has announced the pre-release of its financial reports for the fiscal year 2024/25, covering the period from October 1, 2024, to September 30, 2025. The reports, including both the year report and the group year report, are scheduled to be published on January 29, 2026, on their website. This announcement is significant as it provides stakeholders with a timeline for when they can expect detailed financial insights, potentially impacting investor decisions and market perceptions.

The most recent analyst rating on (DE:HNL) stock is a Hold with a EUR8.50 price target. To see the full list of analyst forecasts on Dr. Hoenle AG stock, see the DE:HNL Stock Forecast page.

Leadership Change at Dr. Hoenle AG: Dr. Markus Arendt Departs Management Board

Dr. Hoenle AG announced the departure of Dr. Markus Arendt from its Management Board effective September 14, 2025, due to differing views on the company’s strategic direction. Dr. Franz Richter, the current Chairman of the Supervisory Board, will join the Management Board starting October 1, 2025, with his Supervisory Board mandate suspended during this period. The company remains focused on delivering planned growth and enhancing profitability. The Supervisory Board expressed gratitude for Dr. Arendt’s service and wished him well for the future.

The most recent analyst rating on (DE:HNL) stock is a Sell with a EUR8.00 price target. To see the full list of analyst forecasts on Dr. Hoenle AG stock, see the DE:HNL Stock Forecast page.

Dr. Hönle AG Revises Financial Forecast for 2024/25

Dr. Hönle AG has adjusted its financial forecast for the fiscal year 2024/25, anticipating revenues between €92 million and €94 million, down from the previous year’s €98.7 million. Despite the lower revenue expectations, the company projects an operating result before depreciation and amortization (EBITDA) between €5 million and €6 million, thanks to cost-cutting measures. This adjustment reflects the company’s strategic response to current market conditions and aims to maintain operational efficiency, potentially impacting stakeholders and the company’s market positioning.

The most recent analyst rating on (DE:HNL) stock is a Buy with a EUR22.00 price target. To see the full list of analyst forecasts on Dr. Hoenle AG stock, see the DE:HNL Stock Forecast page.